{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:05:46Z","timestamp":1794737146196,"version":"4.9.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eururo.2026.01.027","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:44:40Z","timestamp":1770381880000},"page":"479-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma"],"prefix":"10.1016","volume":"89","author":[{"given":"Brigida Anna","family":"Maiorano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli","family":"Dizman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.01.027_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70020","article-title":"Top advances of the year: bladder cancer","volume":"131","author":"Apolo","year":"2025","journal-title":"Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2026.01.027_b0010","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.2024.42.4_suppl.574","article-title":"HER2 mutation and bladder cancer (BC): prevalence and clinical outcomes","volume":"42","author":"Shah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2026.01.027_b0015","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1200\/JCO.2025.43.5_suppl.828","article-title":"Molecular subtypes, NECTIN4\/HER2 expression, and clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) or muscle invasive bladder cancer (MIBC): exploratory analyses from JAVELIN Bladder 100 and the Tempus database","volume":"43","author":"Eckstein","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.027_b0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.027_b0025","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2026.01.027_b0030","doi-asserted-by":"crossref","first-page":"S1138","DOI":"10.1016\/j.annonc.2024.08.2052","article-title":"1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la\/mUC): RC48G001 cohort C","volume":"35","author":"Galsky","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.01.027_b0035","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.027_b0040","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2026.01.027_b0045","doi-asserted-by":"crossref","first-page":"S1648","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2026.01.027_b0050","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JCO.2025.43.5_suppl.665","article-title":"Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: updated efficacy and safety results from the phase II RC48-C017 trial","volume":"43","author":"Sheng","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:34:13Z","timestamp":1779917653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0302283826000539"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.027","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}